OncoMatch/Clinical Trials/NCT06134388
Sulfasalazine in Patients With Metastatic Colorectal Cancer
Is NCT06134388 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Sulfasalazine for metastatic colorectal cancer.
Treatment: Sulfasalazine — The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in patients with metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
hemoglobin, erythrocytes, platelets, leukocytes and ANC < grade 2 according to NCI-CTCAE v 5.0
Kidney function
eCrCl, SCr < grade 2 according to NCI-CTCAE v 5.0
Liver function
ALT and AST < grade 2 according to NCI-CTCAE v 5.0
Adequate liver function (ALT and AST < grade 2) according to NCI-CTCAE v 5.0; Adequate renal function (eCrCl, SCr < grade 2) according to NCI-CTCAE v 5.0; Adequate hematological parameters (hemoglobin, erythrocytes, platelets, leukocytes and ANC < grade 2 according to NCI-CTCAE v 5.0)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06134388 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages